Sign In
Buy BMRN
$54.66
+1.34 (+2.51%)
At Close: Jun 03, 2026
BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing
04:25pm, Thursday, 24'th Nov 2022 Zacks Investment Research
The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.
BioMarin (BMRN) Up After FDA Scraps AdCom Meet for BLA Filing
12:47pm, Thursday, 24'th Nov 2022
The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.
Canceled AdCom, UniQure's Hemgenix Approval Show Positive Signs For BioMarin's Hemophilia Candidate
06:40pm, Wednesday, 23'rd Nov 2022 Benzinga
Earlier today, the FDA notified BioMarin Pharmaceutical Inc (NASDAQ: BMRN) that the agency no longer plans to hold an advisory committee meeting to discuss the Biologics License Application (BLA)
Why Biomarin Pharmaceutical Stock Hit A New 52-Week High Today - Biomarin Pharmaceutical (NASDAQ:BMRN)
10:19am, Wednesday, 23'rd Nov 2022
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are trading higher by 6.97% to $97.54 Wednesday morning after the company announced advancements in the FDA review of ROCTAVIAN for adults with severe
$1.4 Million Bet On This Real Estate Stock? 3 Stocks Insiders Are Buying
01:49pm, Thursday, 03'rd Nov 2022 Benzinga
Although US stocks closed lower on Wednesday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the sto
Expert Ratings for Biomarin Pharmaceutical
07:22pm, Monday, 31'st Oct 2022 Benzinga
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
9
1
0
10 Analysts Have This to Say About Biomarin Pharmaceutical
02:33pm, Monday, 31'st Oct 2022 Benzinga
Over the past 3 months, 10 analysts have published their opinion on Biomarin Pharmaceutical (NASDAQ:BMRN) stock. These analysts are typically employed by large Wall Street banks and tasked with unders
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
02:13pm, Monday, 31'st Oct 2022 Benzinga
Upgrades
Morgan Stanley upgraded the previous rating for Pure Storage Inc (NYSE:PSTG) from Equal-Weight to Overweight. In the second quarter, Pure Storage showed an EPS of $0.32, compared to $0.14 fr
Mastercard To $428? Plus This Analyst Slashes PT On Intel
12:28pm, Monday, 31'st Oct 2022 Benzinga
Barclays cut the price target on Mastercard Incorporated (NYSE: MA) from $430 to $428. Barclays analyst Ramsey El-Assal maintained an Overweight rating on the stock. Mastercard shares fell 0.6% to $3
Why BioMarin Pharmaceuticals Fell 6.9% on Thursday
10:27pm, Thursday, 27'th Oct 2022 The Motley Fool
Investors were expecting better top-line numbers from the company's earnings report.
Why BioMarin Pharmaceuticals Fell 6.9% on Thursday
06:27pm, Thursday, 27'th Oct 2022
Investors were expecting better top-line numbers from the company's earnings report.
BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View
04:26pm, Thursday, 27'th Oct 2022 Zacks Investment Research
BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.
BioMarin Pharmaceutical (BMRN) Surpasses Q3 Earnings Estimates
10:55pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
BioMarin (BMRN) delivered earnings and revenue surprises of 21.62% and 1.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Biomarin Pharmaceutical, Inc. (BMRN) Q3 2022 Earnings Call Transcript
10:05pm, Wednesday, 26'th Oct 2022
Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN ) Q3 2022 Earnings Conference Call October 26, 2022 4:30 PM ET Company Participants Traci McCarty - VP, IR J.J. Bienaime - Chairman & CEO Jeffrey Ajer - EVP
BioMarin Pharmaceutical (BMRN) Surpasses Q3 Earnings Estimates
08:20pm, Wednesday, 26'th Oct 2022
BioMarin (BMRN) delivered earnings and revenue surprises of 21.62% and 1.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
